Bioequivalence is the easy partand thats exactly why so many pharma wins stall at the finish line.
If youve spent any time in development, you know the script: show that your product performs close enough to the referencewithin accepted clinical and an…

Pharmas next decade wont be won by who files the mostitll be won by who avoids the safe portfolio trap.
Drugmakers have spent years optimizing for predictability: fewer filings, lower upfront legal spend, narrower scope, and portfolios engineered to lo…

If youve ever thought a Paragraph IV notice letter is just paperwork, heres your reminder: one bad filing can cost real money, years of time, and leverage you cant get back.
Drug Patent Watchs latest analysis of a high-profile $50 million dispute lays …

The At-Risk Launch: When the Math Says Go Even If the Court Says No
A case is pending. An injunction is in the docket. The legal posture looksat least on paperlike a stop sign.
And then the spreadsheets win.
In pharma, the at-risk launch is the industr…

Evergreen the old-fashioned wayby building an orchard of patentssounds clever in theory. In practice, it can look a lot like a thicket: dozens of new patents that delay generic entry, inflate costs, and test the patience of policymakers, payers, and pa…

Patent litigation is often treated as a long, expensive sloguntil it isnt.
Heres the quiet reality: the early win rarely just ends a case. It can rewire an entire commercial timeline. And in pharma, where regulatory review cycles and launch sequencing …

The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
The loudest promise in generic drug litigation is simple: be the first to file, win 180 days of market exclusivity.
Its a strategy that has made headlines, guided investment dec…

Most in-house counsel treat a drug patent settlement like a smart default. Pay the number. Avoid the headline. Move on.
But that default can be expensivefinancially, strategically, and competitivelyespecially in patent litigation where the math is the …

Drug patents are often sold as impenetrable fortressesuntil you zoom in on the real battlefield. The most decisive cracks rarely appear at the main gate. They show up first at the weakest wall: device patents.
Thats the core argument behind this DrugPa…

A new patent didnt solve anythingit just reset the clock.
Drugmakers call it innovation. Patients often experience it as dj vu. And payers? They see the bill come due again.
This is the salt change trap: when a company switches the salt form of an ex…